文献速递妇科

晚期子宫内膜癌患者的真实世界结局:基于美国电子健康记录的回顾性队列研究

Real-world outcomes in patients with advanced endometrial cancer: A retrospective cohort study of US electronic health records.
PubMed 文献 · Gynecol Oncol · 2021-12-21

基于美国真实世界数据库电子健康记录,纳入2013年1月1日至2020年9月30日确诊的2202例晚期/复发性子宫内膜癌成年女性,评估不同组织学亚型的生存结局。从首次系统治疗起,子宫浆液性癌和其他亚型的中位总生存期短于子宫内膜样癌,黑种人女性结局更差。

要点

  • 多数患者(82.7%)在社区机构接受治疗,74.0%初诊即为III/IV期。
  • 首次系统治疗以铂类联合化疗为主(82.0%)。
  • 子宫浆液性癌和其他亚型的中位总生存期短于子宫内膜样癌。

核心结论

  • 晚期/复发性子宫内膜癌女性生存结局差,需要更有效的治疗。

研究设计与样本

  • 回顾性队列研究,使用美国真实世界数据库电子健康记录,纳入2013年1月1日至2020年9月30日确诊的晚期/复发性子宫内膜癌成年女性2202例。

主要发现

  • 中位总生存期(95%CI)从首次系统治疗起:子宫浆液性癌31.3(27.7-34.3)个月,其他亚型29.4(21.4-43.9)个月,子宫内膜样癌70.8(60.5-83.2)个月。
  • 至首次后续治疗或死亡时间(TFST)观察到类似结果。
  • 黑种人/非裔美国女性总生存期和TFST均差于白种人女性。

关键数值与推荐

  • 子宫内膜样癌占59.8%,子宫浆液性癌占25.0%,其他亚型占15.2%。
  • 首次系统治疗为铂类联合化疗者占82.0%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To characterize clinical outcomes of women with advanced/recurrent endometrial cancer (AEC) in routine practice using electronic health records from a real-world database. METHODS: Adult women diagnosed with AEC (stage III/IV, or early stage with locoregional/distant recurrence) between January 1, 2013 and September 30, 2020, inclusive, were eligible provided they received platinum-based chemotherapy at any time following diagnosis and had ≥2 clinical visits. Follow-up was from initiation of systemic treatment after advanced diagnosis (index) until March 30, 2021, last available follow-up, or death, whichever occurred first. Outcomes, by histological subtype, included Kaplan-Meier estimates of overall survival (OS) and time to first subsequent therapy or death (TFST). RESULTS: Of the 2202 women with AEC, most were treated in a community setting (82.7%) and presented with stage III/IV disease at initial diagnosis (74.0%). The proportion with endometrioid carcinoma, uterine serous carcinoma (USC), and other AEC subtypes was 59.8%, 25.0%, and 15.2%, respectively. The most common first systemic treatment following advanced/recurrent diagnosis was platinum-based combination chemotherapy (82.0%). Median OS (95% CI) from initiation of first systemic treatment was shorter with USC (31.3 [27.7-34.3] months) and other AECs (29.4 [21.4-43.9] months) versus endometrioid carcinoma (70.8 [60.5-83.2] months). Similar results were observed for TFST. Black/African American women had worse OS and TFST than white women. CONCLUSIONS: Women with AEC had poor survival outcomes, demonstrating the requirement for more effective therapies. To our knowledge, this is the most comprehensive evaluation of contemporary treatment of AEC delivered in a community setting to date.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Monk BJ, Smith G, Lima J, et al. Real-world outcomes in patients with advanced endometrial cancer: A retrospective cohort study of US electronic health records. Gynecol Oncol. 2021. PMID: 34952707. doi:10.1016/j.ygyno.2021.12.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。